Alan Huang, Chief Scientific Officer of Tango Therapeutics, joined the company after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango.

Alan brings over 15 years of experience in oncology translational research, target discovery, and drug development, most recently from Novartis Institute for Biomedical Research. As Senior Director and interim Global Head of Oncology Translational Research, Alan was responsible for generating trial-enabling pre-clinical concepts, and under his leadership, the group advanced many key compounds through development and registration. In his earlier roles, Alan was responsible for a variety of drug discovery and target ID platforms in oncology research, most notably pioneering the pooled shRNA-based screening technology. Prior to joining Novartis, Alan worked at Millennium Pharmaceuticals as a senior scientist focusing on the discovery of novel targets to treat metabolic diseases.

Alan obtained his Bachelor of Science in biochemistry from Fudan University and his doctorate in biochemistry & molecular biology from the University of South Alabama. He completed a postdoctoral fellowship at Schepen’s Eye Research Institute of Harvard Medical School, studying the role of BCL2 in CNS axonal regeneration. Alan is an author of over 30 peer-reviewed publications and an inventor of nearly 20 patents.